vs
AXT INC（AXTI）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是AXT INC的1.5倍（$35.5M vs $23.0M），AXT INC净利率更高（-15.4% vs -304.2%，领先288.8%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -8.2%），AXT INC自由现金流更多（$1.3M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 0.8%）
AXT Inc是一家专业的化合物半导体衬底制造商，主营砷化镓、磷化铟、锗晶圆等产品，其生产的高性能衬底广泛应用于通信、消费电子、工业领域的光电子及射频器件制造环节。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
AXTI vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.5倍
$23.0M
营收增速更快
RXRX
高出690.0%
-8.2%
净利率更高
AXTI
高出288.8%
-304.2%
自由现金流更多
AXTI
多$48.6M
$-47.3M
两年增速更快
RXRX
近两年复合增速
0.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.0M | $35.5M |
| 净利润 | $-3.5M | $-108.1M |
| 毛利率 | 20.9% | 59.8% |
| 营业利润率 | -16.6% | -304.8% |
| 净利率 | -15.4% | -304.2% |
| 营收同比 | -8.2% | 681.7% |
| 净利润同比 | 30.3% | 39.6% |
| 每股收益（稀释后） | $-0.09 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXTIRXRX
| Q4 25 | $23.0M | $35.5M | ||
| Q3 25 | $28.0M | $5.2M | ||
| Q2 25 | $18.0M | $19.2M | ||
| Q1 25 | $19.4M | $14.7M | ||
| Q4 24 | $25.1M | $4.5M | ||
| Q3 24 | $23.6M | $26.1M | ||
| Q2 24 | $27.9M | $14.4M | ||
| Q1 24 | $22.7M | $13.8M |
净利润AXTIRXRX
| Q4 25 | $-3.5M | $-108.1M | ||
| Q3 25 | $-1.9M | $-162.3M | ||
| Q2 25 | $-7.0M | $-171.9M | ||
| Q1 25 | $-8.8M | $-202.5M | ||
| Q4 24 | $-5.1M | $-178.9M | ||
| Q3 24 | $-2.9M | $-95.8M | ||
| Q2 24 | $-1.5M | $-97.5M | ||
| Q1 24 | $-2.1M | $-91.4M |
毛利率AXTIRXRX
| Q4 25 | 20.9% | 59.8% | ||
| Q3 25 | 22.3% | -183.8% | ||
| Q2 25 | 8.0% | -4.9% | ||
| Q1 25 | -6.4% | -48.0% | ||
| Q4 24 | 17.6% | -181.4% | ||
| Q3 24 | 24.0% | 53.7% | ||
| Q2 24 | 27.4% | 36.2% | ||
| Q1 24 | 26.9% | 19.1% |
营业利润率AXTIRXRX
| Q4 25 | -16.6% | -304.8% | ||
| Q3 25 | -4.0% | -3327.6% | ||
| Q2 25 | -37.5% | -916.8% | ||
| Q1 25 | -53.1% | -1297.9% | ||
| Q4 24 | -24.6% | -4042.4% | ||
| Q3 24 | -14.4% | -377.1% | ||
| Q2 24 | -6.8% | -697.4% | ||
| Q1 24 | -14.8% | -698.4% |
净利率AXTIRXRX
| Q4 25 | -15.4% | -304.2% | ||
| Q3 25 | -6.8% | -3135.3% | ||
| Q2 25 | -39.0% | -894.2% | ||
| Q1 25 | -45.5% | -1373.3% | ||
| Q4 24 | -20.3% | -3935.5% | ||
| Q3 24 | -12.4% | -367.5% | ||
| Q2 24 | -5.4% | -676.6% | ||
| Q1 24 | -9.2% | -662.4% |
每股收益（稀释后）AXTIRXRX
| Q4 25 | $-0.09 | $-0.17 | ||
| Q3 25 | $-0.04 | $-0.36 | ||
| Q2 25 | $-0.16 | $-0.41 | ||
| Q1 25 | $-0.20 | $-0.50 | ||
| Q4 24 | $-0.11 | $-0.56 | ||
| Q3 24 | $-0.07 | $-0.34 | ||
| Q2 24 | $-0.04 | $-0.40 | ||
| Q1 24 | $-0.05 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $120.3M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $273.3M | $1.1B |
| 总资产 | $433.8M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资AXTIRXRX
| Q4 25 | $120.3M | $743.3M | ||
| Q3 25 | $23.1M | $659.8M | ||
| Q2 25 | $27.0M | $525.1M | ||
| Q1 25 | $31.6M | $500.5M | ||
| Q4 24 | $22.8M | $594.4M | ||
| Q3 24 | $24.9M | $427.6M | ||
| Q2 24 | $29.5M | $474.3M | ||
| Q1 24 | $27.5M | $296.3M |
总债务AXTIRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益AXTIRXRX
| Q4 25 | $273.3M | $1.1B | ||
| Q3 25 | $179.1M | $1.0B | ||
| Q2 25 | $179.7M | $919.1M | ||
| Q1 25 | $185.0M | $933.9M | ||
| Q4 24 | $192.8M | $1.0B | ||
| Q3 24 | $200.7M | $524.6M | ||
| Q2 24 | $199.7M | $584.4M | ||
| Q1 24 | $201.1M | $401.2M |
总资产AXTIRXRX
| Q4 25 | $433.8M | $1.5B | ||
| Q3 25 | $334.0M | $1.4B | ||
| Q2 25 | $329.0M | $1.3B | ||
| Q1 25 | $333.5M | $1.3B | ||
| Q4 24 | $339.3M | $1.4B | ||
| Q3 24 | $355.6M | $726.5M | ||
| Q2 24 | $349.4M | $775.9M | ||
| Q1 24 | $349.0M | $557.8M |
负债/权益比AXTIRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $1.3M | $-47.3M |
| 自由现金流率自由现金流/营收 | 5.5% | -133.1% |
| 资本支出强度资本支出/营收 | 13.2% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-18.8M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流AXTIRXRX
| Q4 25 | $4.3M | $-46.1M | ||
| Q3 25 | $-9.2M | $-117.4M | ||
| Q2 25 | $-4.6M | $-76.4M | ||
| Q1 25 | $-3.3M | $-132.0M | ||
| Q4 24 | $1.3M | $-115.4M | ||
| Q3 24 | $-5.4M | $-59.2M | ||
| Q2 24 | $843.0K | $-82.2M | ||
| Q1 24 | $-8.8M | $-102.3M |
自由现金流AXTIRXRX
| Q4 25 | $1.3M | $-47.3M | ||
| Q3 25 | $-11.3M | $-117.6M | ||
| Q2 25 | $-4.9M | $-79.6M | ||
| Q1 25 | $-3.9M | $-133.8M | ||
| Q4 24 | $1.1M | $-116.7M | ||
| Q3 24 | $-6.4M | $-63.8M | ||
| Q2 24 | $572.0K | $-83.4M | ||
| Q1 24 | $-13.2M | $-109.0M |
自由现金流率AXTIRXRX
| Q4 25 | 5.5% | -133.1% | ||
| Q3 25 | -40.5% | -2272.5% | ||
| Q2 25 | -27.0% | -413.9% | ||
| Q1 25 | -19.9% | -907.4% | ||
| Q4 24 | 4.4% | -2567.7% | ||
| Q3 24 | -26.9% | -244.6% | ||
| Q2 24 | 2.0% | -578.5% | ||
| Q1 24 | -58.2% | -789.9% |
资本支出强度AXTIRXRX
| Q4 25 | 13.2% | 3.5% | ||
| Q3 25 | 7.8% | 4.7% | ||
| Q2 25 | 1.6% | 16.4% | ||
| Q1 25 | 2.6% | 12.4% | ||
| Q4 24 | 0.7% | 28.6% | ||
| Q3 24 | 4.0% | 17.5% | ||
| Q2 24 | 1.0% | 8.2% | ||
| Q1 24 | 19.4% | 48.2% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXTI
| Substrates | $15.3M | 66% |
| Five Minority Investments | $7.8M | 34% |
RXRX
暂无分部数据
